BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 35771624)

  • 1. Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies.
    Rawat P; Sharma D; Prabakaran R; Ridha F; Mohkhedkar M; Janakiraman V; Gromiha MM
    Bioinformatics; 2022 Aug; 38(16):4051-4052. PubMed ID: 35771624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ProCaff: protein-carbohydrate complex binding affinity database.
    Siva Shanmugam NR; Jino Blessy J; Veluraja K; Michael Gromiha M
    Bioinformatics; 2020 Jun; 36(11):3615-3617. PubMed ID: 32119071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.
    Tzou PL; Tao K; Pond SLK; Shafer RW
    PLoS One; 2022; 17(3):e0261045. PubMed ID: 35263335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoV-AbDab: the coronavirus antibody database.
    Raybould MIJ; Kovaltsuk A; Marks C; Deane CM
    Bioinformatics; 2021 May; 37(5):734-735. PubMed ID: 32805021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
    Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
    Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
    Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
    [No Abstract]   [Full Text] [Related]  

  • 13. CoV3D: a database of high resolution coronavirus protein structures.
    Gowthaman R; Guest JD; Yin R; Adolf-Bryfogle J; Schief WR; Pierce BG
    Nucleic Acids Res; 2021 Jan; 49(D1):D282-D287. PubMed ID: 32890396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.
    Du L; Zhao G; Yang Y; Qiu H; Wang L; Kou Z; Tao X; Yu H; Sun S; Tseng CT; Jiang S; Li F; Zhou Y
    J Virol; 2014 Jun; 88(12):7045-53. PubMed ID: 24719424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.
    Verkhivker GM; Agajanian S; Oztas DY; Gupta G
    Biochemistry; 2021 May; 60(19):1459-1484. PubMed ID: 33900725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.
    Cheng L; Song S; Zhou B; Ge X; Yu J; Zhang M; Ju B; Zhang Z
    Virol J; 2021 Apr; 18(1):87. PubMed ID: 33910569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
    Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
    J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
    Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
    Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
    Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.